AWP class action court ruling
Executive Summary
U.S. District Court Judge Patti Saris rules in a class action lawsuit that AstraZeneca, Bristol-Myers Squibb and Schering-Plough subsidiary Warrick acted "unfairly and deceptively" by publishing false and inflated average wholesale prices for their drugs. She dismissed claims against Johnson & Johnson, although she said the company's conduct "was at times troubling." The class action, filed on behalf of two groups of third-party payers, is among more than 90 cases consolidated in multidistrict litigation, In Re Average Wholesale Price Litigation (1"The Pink Sheet" Feb. 12, 2007, p. 23). Saris, a judge for the District Court in Boston, determined damages for one group in the class and said additional information is needed to set damages for the second. She found damages of $4.5 million for AstraZeneca and $183,454 for BMS, and found Warrick's damages for its albuterol pricing are limited to the second group. GlaxoSmithKline settled all claims and AstraZeneca settled claims involving Medicare beneficiaries...
You may also be interested in...
Bristol-Myers Squibb settles AWP suit
Bristol agrees to pay $13 million to settle a class action by plaintiffs who claim their co-payments under Medicare Part B were based on inflated average wholesale prices for Taxol and other Bristol drugs. The June 26 settlement covers Class I claimants in long-running AWP litigation. In a June 21 ruling, Massachusetts U.S. District Court Judge Patti Saris found that Bristol, AstraZeneca and Schering-Plough subsidiary Warrick had published false and inflated AWPs for two other classes of claimants (1"The Pink Sheet" June 25, 2007, In Brief)...
AWP Litigation Increases As Justice Dept. Sues Roxane For Price Inflation
Another lawsuit has been added to the tangle of litigation over average wholesale drug pricing
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.